Inhibitory effect of Fuzheng Yiliuyin in combination with chemotherapeutics on human gastric carcinoma cell strain

Table 1 Effects of ZY in combination with chemotherapeutics on SGC-7901 MGC–803 cell proliferation (mean±SD)

Group	SGC-7901			MGC–803
	24 h	48 h	72 h	24 h	48 h	72 h
ZY	12.4 ± 7.9	17.4 ± 3.1	20.1 ± 5.5	8.9 ± 4.5	11.8 ± 5.4	14.8 ± 2.7
ZY + Vp-16	a51.2 ± 4.2	e56.9 ± 4.8	c62.3 ± 3.9	g36.9 ± 7.2	i48.9 ± 5.2	k58.8 ± 4.6
ZY + ADM	a46.5 ± 7.2	e50.1 ± 3.2	c55.4 ± 48	g34.5 ± 8.1	i43.6 ± 3.7	k50.7 ± 6.4
ZY + 5-Fu	a57.8 ± 2.6	e61.9 ± 6.3	c69.9 ± 8.4	g40.7 ± 6.6	i50.8 ± 4.7	k55.7 ± 3.2
ZY + DDP	a53.6 ± 2.4	e58.4 ± 1.7	c67.4 ± 5.7	g70.2 ± 3.5	i80.1 ± 3.6	k84.3 ± 7.5
ZY + EAP	a61.2 ± 3.3	e68.5 ± 3.9	c71.5 ± 3.4	g73.8 ± 4.6	i72.2 ± 4.1	k74.9 ± 3.4
ZY + EFP	a79.4 ± 2.8	e83.3 ± 4.8	c87.5 ± 4.3	g82.6 ± 7.8	i87.5 ± 3.1	k89.9 ± 4.8

^aP < 0.05 vs 24 h,

^cP < 0.05 vs 48 h,

^eP < 0.05 vs 72 h,

^gP < 0.05 vs 24 h,

ⁱP < 0.05 vs 42 h,

^kP < 0.05 vs 72 h.

Table 2 Effects of ZY in combintion with chemotherapeutics on SGC-7901 MGC–803 cell apoptosis rates (mean±SD)

	SGC-7901			MGC-803
	alive	necrosis	apoptosis	alive	necrosis	apoptosis
ZY	78.7 ± 0.6	6.6 ± 4.3	14.5 ± 5.4	84.4 ± 3.1	4.5 ± 0.6	11.2 ± 1.8
ZY + Vp-16	38.5 ± 2.5	46.1 ± 6.2	15.3 ± 2.1	42.1 ± 1.5	32.4 ± 7.9	25.8 ± 5.2
ZY + ADM	44.6 ± 3.5	26.7 ± 2.5	19.9 ± 4.7	49.4 ± 5.2	29.8 ± 3.3	20.7 ± 5.1
ZY + 5-Fu	29.6 ± 4.1	44.7 ± 9.9	25.6 ± 1.2	44.3 ± 8.2	30.5 ± 7.4	25.3 ± 4.6
ZY + DDP	32.3 ± 11.7	63.6 ± 10.6	4.1 ± 3.0	16.1 ± 7.5	60.9 ± 8.1	23.0 ± 0.6
ZY + EAP	27.6 ± 5.8	55.5 ± 10.5	16.8 ± 7.4	25.0 ± 2.9	65.4 ± 5.8	9.6 ± 2.3
ZY + EFP	13.1 ± 2.7	66.3 ± 12.0	20.7 ± 6.6	11.1 ± 3.6	67.8 ± 4.1	20.9 ± 4.9
control	92.1 ± 6.3	6.6 ± 8.4	1.3 ± 0.2	94.3 ± 0.2	4.6 ± 0.8	1.2 ± 0.5